VolitionRx Limited — Q2 2014 Form 10-Q
Business context and period: Development-stage company focused on cancer diagnostics, including colorectal cancer research and development. This unaudited filing covers the quarter and six months ended June 30, 2014; the comparable periods are 2013. The company reported no operating revenue in either 2014 period.
Financial performance and position
| Metric | Q2 2014 / June 30, 2014 | Comparison / context |
|---|---|---|
| Revenue | $0 | $0 in Q2 2013 |
| Operating expenses | $1.05 million for Q2; $2.29 million for six months | Q2 was broadly flat year over year; six-month expenses rose 17%, mainly from higher R&D activity |
| Net income (loss) | Q2 income of $816,804; six-month loss of $1.38 million | Q2 2013 loss was $1.05 million; six-month 2013 loss was $1.96 million |
| Cash and current assets | Cash of $1.81 million; current assets of $2.01 million | Cash was $888,704 at December 31, 2013 |
| Current liabilities and working capital | Current liabilities of $3.15 million; reported working capital deficit of $1.14 million | Excluding the $2.32 million derivative liability, management reported an operating working capital surplus of $1.17 million |
| Total liabilities / equity | Liabilities of $3.58 million; stockholders’ deficit of $532,347 | Derivative liability was $2.32 million; grant repayable was $429,007 |
| Cash flow | Six-month operating cash used: $2.28 million; investing cash used: $46,671; financing cash provided: $3.26 million | Cash increased $919,567 during the six months |
No meaningful operating margin is available because the company had no operating revenue. The Q2 net profit reflected a $1.87 million gain from remeasurement of warrant-related derivative liabilities, rather than operating performance. The six-month results included a $767,001 net gain from the derivative remeasurement and $143,987 of grant income.
Material changes and unusual items
- Research and development expense rose to $1.66 million for the first six months, from $1.23 million a year earlier; management attributed the increase to patent filings, laboratory supplies, and staff and consultancy costs.
- The company raised $3.0 million in February 2014 through a share issuance with attached five-year warrants, and $352,500 in June through a share issuance. The February warrants’ ratchet provision required derivative-liability accounting and caused substantial noncash valuation changes.
- Common shares outstanding were 13,468,164 as of August 1, 2014. Further equity sales may dilute existing holders.
- Intangible assets, principally patents, were $945,410 at June 30, 2014. No impairment was recorded in the first half of 2014; $350,000 had been impaired in 2013.
Outlook, risks and contingencies
- Management and the filing identify substantial doubt about the company’s ability to continue as a going concern. It has incurred cumulative losses of $12.67 million, has very limited revenue, and depends on additional capital, grants, or financing.
- Management planned to conserve cash, seek grants, and pursue debt or equity financing. There is no assurance financing will be available; delays could defer clinical validation and regulatory work, and continued funding shortfalls could force cessation of operations.
- The Walloon Region grant includes $429,007 repayable in installments through 2023 and a 6% royalty on qualifying product or service revenue, subject to an aggregate cap. The company also extended its Bonn University sample-testing agreement for two years, with payments totaling $532,155.
- Disclosure controls were assessed as ineffective at June 30, 2014 because no board member qualified as an audit committee financial expert. Management reported no significant subsequent change in internal control over financial reporting.
- The company reported no material pending legal proceedings and no significant off-balance-sheet arrangements.
Key facts for investors to verify
- Whether the company can secure sufficient financing and maintain liquidity given operating cash use and the going-concern uncertainty.
- How much of reported earnings and future results depends on noncash warrant-liability remeasurement, and how warrant terms could affect dilution or liabilities.
- Progress, timing, and funding needs for clinical validation and regulatory approval, and the prospects for generating revenue.
- The terms and potential impact of grant repayment and royalty obligations, related-party service costs, and the Bonn University agreement.
- Whether governance and disclosure-control weaknesses are addressed.